H. Lundbeck A/S

HLUN A

Equity

ISIN DK0061804697 / Valor 119252584

Nasdaq Copenhagen Equities (2025-04-04)

DKK 25.50-6.59%

H. Lundbeck A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

H. Lundbeck A/S is a globally recognized pharmaceutical company headquartered in Denmark, with a specialized focus on developing treatments for brain diseases. Founded over a century ago by Hans Lundbeck, the company has established a significant presence in the neuroscience field, dedicating more than 70 years to the development and distribution of pioneering therapies. With a workforce of approximately 5,500 employees spread across more than 50 countries, Lundbeck operates production facilities in Denmark, France, and Italy, alongside research centers in Denmark and the US. The company's portfolio, which is registered in over 100 countries, reaches more than 8 million people daily. As of 2023, Lundbeck reported a revenue of DKK 19.9 billion, with its largest markets including the US, China, Canada, and several European countries, among others. The Lundbeck Foundation, holding about 70% of the company's shares, significantly supports medical research and educational initiatives with its annual grants.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In 2023, H. Lundbeck A/S reported a significant increase in revenue, reaching DKK 19,912 million compared to DKK 18,246 million in 2022. This growth was primarily driven by strong performance in the U.S. and European markets.

Strategic Brands Performance

The revenue from H. Lundbeck A/S's strategic brands saw a notable increase of 13% (+16% CER), amounting to DKK 13,733 million. These strategic brands now represent 69% of the company's total revenue for 2023.

Profitability Metrics

H. Lundbeck A/S achieved a net profit of DKK 2,290 million in 2023. The company's operating profit before depreciation and amortization (EBITDA) was reported at DKK 5,207 million, reflecting a robust financial performance.

Cash Position

As of 2023, H. Lundbeck A/S maintained a net cash position of DKK 711 million, indicating a strong liquidity position to support future investments and operational needs.

Future Outlook

H. Lundbeck A/S is focused on long-term sustainable growth, with plans to invest further in research and development. The company aims to expand its presence in neuroscience and specialty neurology, leveraging recent acquisitions and strategic partnerships.

Summarized from source with an LLMView Source

Key figures

-12.7%1Y

-21.3%3Y

-38.5%5Y

Performance

40.1%1Y

34.5%3Y

32.9%5Y

Volatility